Preview

Опухоли женской репродуктивной системы

Расширенный поиск

ИНГИБИТОР ЦИКЛИНЗАВИСИМЫХ КИНАЗ ПАЛБОЦИКЛИБ – НОВЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ МЕТАСТАТИЧЕСКОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.17650/1994-4098-2017-13-4-34-43

Полный текст:

Аннотация

Последовательное применение нескольких линий гормональной терапии считается стандартом лечения метастатического рака молочной железы, экспрессирующего рецепторы эстрогенов или прогестерона. Исследования PALOMA-1, -2 и -3 показали, что сочетание ингибитора CDK4/6 палбоциклиба с гормональной терапией значительно увеличивает время до прогрессирования по сравнению с монотерапией антагонистами сигнального каскада эстрогенов.

Об авторах

Е. Н. Имянитов
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВО «Cеверо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России; ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России
Россия

Евгений Наумович Имянитов.

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 191015 Санкт-Петербург, ул. Кирочная, 41; 194100 Санкт-Петербург, ул. Литовская, 2



Т. Ю. Семиглазова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВО «Cеверо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия

Татьяна Юрьевна Семиглазова.

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 191015 Санкт-Петербург, ул. Кирочная, 41



Список литературы

1. Mohammed H., Russell I.A., Stark R. et al. Progesterone receptor modulates ERα action in breast cancer. Nature 2015;523(7560):313–7. DOI: 10.1038/nature14583.

2. Groenendijk F.H., Zwart W., Floore A. et al. Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics. Breast Cancer Res Treat 2013;140(3):475–84. DOI: 10.1007/s10549-013-2648-1.

3. Iyevleva A.G., Imyanitov E.N. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract 2016;14(1):17. DOI: 10.1186/s13053-016-0057-2.

4. Rugo H.S., Rumble R.B., Macrae E. et al. Endocrine therapy for hormone-receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016;34(25):3069–103. DOI: 10.1200/JCO.2016.67.1487.

5. Curigliano G., Burstein H., Winer E. et al. De-escalating end escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017;28(8):1700–12. DOI: 10.1093/annonc/mdx308.

6. Cтуков А.Н., Бланк М.А., Семиглазова Т.Ю. и др. Фармакотерапия опухолей (Посвящается памяти М.Л. Гершановича). Под ред. А.Н. Стукова, М.А. Бланка, Т.Ю. Семиглазовой, А.М. Беляева. СПб.: Вопросы онкологии, 2017. С. 238–69. [Stukov A.N., Blanc M.A., Semiglazova T.Y. et al. Pharmacotherapy of tumors (Dedicated to the memory of M.L. Gershanovich). Eds.: A.N. Stukov, M.A. Blanc, T.Y. Semiglazova, A.M. Belyaev. SPb.: Voprosy onkologii, 2017. Р. 238–69. (In Russ.)].

7. Llombart-Cussac A., Pivot X.B., Biganzoli L. et al. A prognostic factor (PF) index for overall survival in a HER2-negative endocrine resistant metastatic breast cancer (MBC) population: analysis from the ATHENA trial. ASCO 2013. J Clin Oncol 2013;31(suppl):555.

8. Llombart-Cussac A., Pivot X.B., Biganzoli L. et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast 2014;23(5):656–62. DOI: 10.1016/j.breast.2014.06.017.

9. Theriault R.L., Litton J.K., Mittendorf E.A. et al. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011;11(5):325–231. DOI: 10.1016/j.clbc.2011.05.002.

10. Colzani E., Liljegren A., Johansson A.L. et al. Prognosis of patients with breastcancer: causes of death and effects of time since diagnosis, age and tumor characteristics. J Clin Oncol 2011;29(30):4014–21. DOI: 10.1200/JCO.2010.32.6462.

11. Kim I.K., Park S., Hwang H. et al. Clinical significance of age at the time of diagnosis among young breast cancer patients. J Breast Cancer 2011;14(4): 314–21. DOI: 10.4048/jbc.2011.14.4.314.

12. Van de Water W., Bastiaannet E., Hille E.T. et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone-receptor-positive breast cancer: a TEAM study analysis. Oncologist 2012;17(1):55–63. DOI: 10.1634/theoncologist.2011-0037.

13. Gazet J.C., Sutcliffe R. A randomized trial comparing tamoxifen versus surgery in patients over the age of 70 with operable breast cancer – final results after 28 years of follow-up. Eur J Surg Oncol 2011;37(9):754–7. DOI: 10.1016/j.ejso.2011.06.011.

14. СтенинаМ.Б., ЖуковаЛ.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. М.: Практические рекомендации RUSSCO, версия 2016. C. 97–122. [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical recommendations on the medicinal treatment of invasive breast cancer. Moscow: Practical recommendations of RUSSCO, version 2016. Pp. 97–122. (In Russ.)].

15. Lobbezoo D.J., van Kampen R.J., Voogd A.C. et al. In real life, one-quarter of patients with hormone-receptorpositive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 2016;27(2):256–62. DOI: 10.1093/annonc/mdv544.

16. Cardoso F., Costa A., Norton L. et al. ESO/ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014;25(10): 1871–88. DOI: 10.1093/annonc/mdu385.

17. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2017. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

18. Robertson J.F.R., Bondarenko I.M., Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormonereceptor-positive advanced breast cancer (FALCON): an international, randomized, double-blind, phase 3 trial. Lancet 2016;388(10063):2997–3005. DOI: 10.1016/S0140-6736(16)32389-3.

19. Pritchard K.I. Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 2008;112(3 suppl):718–22. DOI: 10.1002/cncr.23189.

20. Baselga J., Campone M., Piccart M. et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520–9. DOI: 10.1056/NEJMoa1109653.

21. Finn R.S., Crown J.P., Lang I. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen-receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet Oncol 2015;16(1):25–35. DOI: 10.1016/S1470-2045(14)71159-3.

22. Finn R.S., Martin M., Rugo H.S. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925–36. DOI: 10.1056/NEJMoa1607303.

23. Finn R.S., Crown J.P., Ettl J. et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 2016;18(1):67. DOI: 10.1186/s13058-016-0721-5.

24. Clinical Review IBRANCE (Palbociclib) Beaver (efficacy) and Amiri (safety) NDA 207,103. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000MedR.pdf.

25. Finn R.S., Martin M., Rugo H.S. et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2–-advanced breast cancer (ABC). J Clin Oncol 2016;34(suppl):507.

26. Turner N.C., Ro J., Andre F. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373(3):209–19. DOI: 10.1056/NEJMoa1505270.

27. Cristofanilli M., Turner N.C., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17(4):425–39. DOI: 10.1016/S1470-2045(15)00613-0.

28. Cristofanilli M., Bondarenko I., Ro J. et al. PALOMA3: phase 3 trial of fulvestrant with or without palbociclib in preand postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy – confirmed efficacy and safety. Poster presented at SABCS 2015, San Antonio, Texas, USA (Abstract 4-13-01).

29. Verma S., Bartlett C.H., Schnell P. et al. Palbociclib in combination with fulvestrant in women with hormone-receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebocontrolled, phase III study (PALOMA-3). Oncologyst 2016;21(10):1165–75. DOI: 10.1634/theoncologist.2016-0097.

30. Diéras V., Rugo H.S., Gelmon K. et al. Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+HER2–-advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies. Poster presented at SABCS 2016 (Abstract P4-22-07).

31. Harbeck N., Iyer S., Cristofanilli M. et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016;27(6):1047–54. DOI: 10.1093/annonc/mdw139.

32. Finn R.S., Crown J.P., Lang I. et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2–-advanced breast cancer (PALOMA-1, TRIO-18). J Clin Oncol 2017;35(suppl):1001. DOI: 10.1200/JCO.2017.35.15_suppl.1001.


Для цитирования:


Имянитов Е.Н., Семиглазова Т.Ю. ИНГИБИТОР ЦИКЛИНЗАВИСИМЫХ КИНАЗ ПАЛБОЦИКЛИБ – НОВЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ МЕТАСТАТИЧЕСКОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ. Опухоли женской репродуктивной системы. 2017;13(4):34-43. https://doi.org/10.17650/1994-4098-2017-13-4-34-43

For citation:


Imyanitov E.N., Semiglazova T.Y. CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER. Tumors of female reproductive system. 2017;13(4):34-43. (In Russ.) https://doi.org/10.17650/1994-4098-2017-13-4-34-43

Просмотров: 206


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)